Asensus Surgical, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-18: Form 8-K; Period of report 2017-12-15; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2017-11-13: Form 8-K; Period of report 2017-11-13; Description 8.01 Other Events; Details 8.01.
- 2017-11-13: Form 8-K; Period of report 2017-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-10-23: Form 8-K; Period of report 2017-10-17; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-18 | 8-K | 2017-12-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | htm_55671.htm |
| 2017-11-13 | 8-K | 2017-11-13 | 8.01 Other Events | 8.01 On November 13, 2017, TransEnterix, Inc. (the "Company") announced that it had entered into agreements to sell the Company’s Senhance™ Surgical Robotic System to Adventist Health System/Sunbelt, Inc. d/b/a Florida Hospital Orlando. | htm_55561.htm |
| 2017-11-13 | 8-K | 2017-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2017, TransEnterix, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2017. | d494452d8k.htm |
| 2017-10-23 | 8-K | 2017-10-17 | 8.01 Other Events | 8.01 On October 17, 2017, TransEnterix, Inc. (the "Company") held an investor call to discuss the U.S. Food and Drug Administration’s ("FDA") clearance of the Company’s Senhance™ Surgical Robotic System. | htm_55472.htm |
| 2017-10-20 | 8-K | 2017-10-18 | 8.01 Other Events | 8.01 On October 20, 2017, Form 4 reports were filed to reflect stock transactions made by Todd M. Pope, the Chief Executive Officer of TransEnterix, Inc. (the "Company"). | htm_55471.htm |
| 2017-10-17 | 8-K | 2017-10-13 | 8.01 Other Events | 8.01 On October 13, 2017, TransEnterix, Inc. (the "Company") announced that the Company has received clearance from the U.S. Food and Drug Administration ("FDA") for its Senhance™ Surgical Robotic System under Section 510(k) of the Food, Drug and Cosmetic Act. | htm_55454.htm |
| 2017-10-10 | 8-K | 2017-10-06 | 8.01 Other Events | 8.01 On October 6, 2017, the U.S. District Court for the Eastern District of North Carolina entered final judgment in favor of TransEnterix, Inc. and all other defendants dismissing the putative securities class action complaint against them in The TransEnterix, Inc. Investor Group v. | htm_55434.htm |
| 2017-09-18 | 8-K | 2017-09-18 | 8.01 Other Events | 8.01 On September 18, 2017, TransEnterix, Inc. (the "Company") issued a press release to disclose that it had filed its response to the U.S. Food and Drug Administration’s Additional Information request related to the Company’s Senhance Surgical Robotic System 510(k) submission. | htm_55361.htm |
| 2017-08-31 | 8-K | 2017-08-31 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. 1.02 On August 31, 2017, the Company terminated that certain Controlled Equity OfferingSM Sales Agreement, dated as of February 9, 2016 with Cantor Fitzgerald & Co. The effective date of termination is September 10, 2017. | htm_55302.htm |
| 2017-08-04 | 8-K | 2017-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2017, TransEnterix, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the second quarter ended June 30, 2017. | htm_55232.htm |
| 2017-06-06 | 8-K | 2017-06-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective June 1, 2017, Anthony Fernando, was appointed as the Chief Operating Officer of TransEnterix, Inc. (the “Company”). | htm_55025.htm |
| 2017-05-25 | 8-K | 2017-05-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On May 25, 2017, at the Annual Meeting of Stockholders for 2017 (the “Annual Meeting”), the stockholders of TransEnterix, Inc. (the “Company”) voted to approve, among other things, an Amendment to the Company’s Amended and Restated Incentive Compensation Plan, as amended (the “Plan”), to increase the number of shares reserved for issuance under the Plan by 7,000,000 shares. 5.07 On May 25, 2017, the Company held its Annual Meeting for 2017. | htm_54988.htm |
| 2017-05-12 | 8-K | 2017-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2017, TransEnterix, Inc., a Delaware corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2017. | htm_54928.htm |
| 2017-05-10 | 8-K | 2017-05-10 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.03 Material Modification to Rights of Security Holders; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 The Company entered into a payoff letter dated as of May 10, 2017, with Silicon Valley Bank and Oxford Finance LLC pursuant to which the Company terminated that certain Amended and Restated Loan and Security Agreement, dated September 26, 2014, by and among the Company and its subsidiaries, Silicon Valley Bank, as Lender and Oxford Finance LLC as Lender and Collateral Agent, as amended by the First Amendment to Amended and Restated Loan and Security Agreement dated August 14, 2015, the Consent and Second Amendment to Amended and Restated Loan Agreement dated September 18, 2015, the Third Amendment to Amended and Restated Loan and Security Agreement dated November 13, 2015, the Consent and Fourth Amendment to Amended and Restated Loan and Security Agreement dated April 19, 2016 and the Fifth Amendment to Amended and Restated Loan and Security Agreement dated September 7, 2016 (collectively, the “SVB Loan Agreement”). 2.03 The information disclosed under Item 1.01 of this Current Report on Form 8-K is incorporated by reference under this Item 2.03. 3.03 The Loan Agreement imposes restrictions on the Company’s ability to declare dividends. 8.01 The Company issued a press release on May 10, 2017, announcing its entry into the Loan Agreement. | d554083d8k.htm |
| 2017-05-03 | 8-K | 2017-05-03 | 8.01 Other Events | 8.01 As previously reported on Form 8-K filed with the Securities and Exchange Commission on April 28, 2017, TransEnterix, Inc. (the "Company") entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated on April 28, 2017, relating to an underwritten public offering of an aggregate of 24,900,000 units (the "Units") each consisting of one share of the Company’s common stock, par value $0.001 per share (the "Common Stock"), a Series A warrant to purchase one share of Common Stock, and a Series B warrant to purchase 0.75 shares of Common Stock. | htm_54891.htm |
| 2017-04-28 | 8-K | 2017-04-27 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 1.02 Effective April 27, 2017, the Company terminated that certain Purchase Agreement dated as of December 16, 2016 (the “Purchase Agreement”), between the Company and Lincoln Park Capital Fund, LLC (“LPC”). 8.01 The Company issued a press release on April 28, 2017, announcing the pricing of the sale of the Units. | d388217d8k.htm |
| 2017-03-08 | 8-K | 2017-03-06 | 2.02 Results of Operations and Financial Condition | 2.02 On March 6, 2017, TransEnterix, Inc., a Delaware corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2016. | htm_54672.htm |
| 2017-02-23 | 8-K | 2017-02-23 | 8.01 Other Events | 8.01 On February 23, 2017, TransEnterix, Inc. announced it has made its second CE-marked ALF-X System sale to a customer in Germany. | htm_54618.htm |
| 2017-01-05 | 8-K | 2016-12-30 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On January 5, 2017, the Company issued a press release announcing its entry into the Amendment and Sofar’s additional equity investment in the Company. | htm_54448.htm |